1. Search Result
Search Result
Results for "

venous thrombosis

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125864
    Fibrinogen (Bovine)
    2 Publications Verification

    Interleukin Related NF-κB Inflammation/Immunology
    Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Fibrinogen (Bovine)
  • HY-153530

    IPK Superfamily Neurological Disease Metabolic Disease
    LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders .
    LI-2242
  • HY-75680

    Factor Xa Cardiovascular Disease
    Apixaban ethyl ester is a key intermediate in the synthesis of FXa inhibitors, which is used to study the inhibitory activity against venous thrombosis .
    Apixaban ethyl ester
  • HY-125864D

    Interleukin Related NF-κB Cardiovascular Disease
    Rabbit Fibrinogen is a native fibrinogen from rabbit plasma. Fibrinogen is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .
    Rabbit Fibrinogen
  • HY-122592

    Factor Xa Cardiovascular Disease
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .
    Zifaxaban
  • HY-A0260

    Biochemical Assay Reagents Cardiovascular Disease
    Ethyl biscoumacetate is an anticoagulant and vitamin K antagonist. Ethyl biscoumacetate can be used in the research of experimental venous thrombosis .
    Ethyl biscoumacetate
  • HY-19219A

    Thrombin Cardiovascular Disease
    BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research .
    BMS-189664 hydrochloride
  • HY-19219

    Thrombin Cardiovascular Disease
    BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC50 of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research .
    BMS-189664
  • HY-119680

    Thrombin Cardiovascular Disease
    AT-1459 is a selective and orally active direct Thrombin inhibitor with a Ki value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases .
    AT-1459
  • HY-10281

    Factor Xa Cardiovascular Disease
    YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .
    YM-60828 methanesulfonate
  • HY-10270

    TGN 255

    Thrombin Cardiovascular Disease
    Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis .
    Flovagatran
  • HY-10271

    TGN 255 sodium

    Thrombin Cardiovascular Disease
    Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis .
    Flovagatran sodium
  • HY-14854A

    ATI-5923 sodium

    VKOR Cardiovascular Disease
    Tecarfarin (ATI-5923) sodium is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin sodium blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin sodium prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin sodium is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin sodium
  • HY-14854R

    ATI-5923 (Standard)

    Reference Standards VKOR Cardiovascular Disease
    Tecarfarin (ATI-5923) (Standard) is the analytical standard of Tecarfarin. This product is intended for research and analytical applications. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin (Standard)
  • HY-14854S

    ATI-5923-13C,d3

    Isotope-Labeled Compounds VKOR Cardiovascular Disease
    Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin-13C,d3
  • HY-120491

    Thrombin Cardiovascular Disease
    L 722151 is a competitive inhibitor for factor XIIIa with Ki of 49 µM. L 722151 accelerates tissue plasminogen activator-catalyzed clot dissolution, and exhibits antithrombotic efficacy .
    L 722151
  • HY-105919

    Factor Xa Cardiovascular Disease
    Naroparcil is an orally active antithrombotic agent. Naroparcil exhibits antithrombotic effects in rabbit Wessler stasis model with EC50s of 21.9 mg/kg and 36.0 mg/kg after respectively intravenous injection and oral administration .
    Naroparcil
  • HY-P2021

    Thrombin Cardiovascular Disease
    BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .
    BMS 180742
  • HY-10279

    Factor Xa Cardiovascular Disease
    YM-60828 hydrochloride is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 hydrochloride inhibits thrombus formation and platelet aggregation. YM-60828 hydrochloride can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .
    YM-60828 hydrochloride
  • HY-164251

    Thrombin Cardiovascular Disease
    RWJ-671818 is an orally active inhibitor of human α-thrombin with a Ki of 1.3 nM. RWJ-671818 can be studied in research on venous and arterial thrombosis .
    RWJ-671818
  • HY-10280S

    Isotope-Labeled Compounds Factor Xa Others
    YM-60828-d3 is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a Ki of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .
    YM-60828-d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: